Quincy Bioscience’s Prevagen Supplement

April 2019: The Spath case was transferred to a court in New York. (Case No. 19-cv-3521, S. D. NY.)

October 2018: The parties agreed to consolidate this case with Vanderwerff v. Quincy Bioscience (Case No. 17-cv-784, D. NJ.), which will be the lead case.

August 2018: A class-action lawsuit was filed against Quincy Bioscience for allegedly falsely marketing the supplement Prevagen as being clinically tested to improve memory within 90 days and support “healthy brain function, sharper mind, and clearer thinking” when, according to plaintiffs, the supplement has not been clinically tested and does not provide the advertised brain and memory benefits. (Spath et al v. Quincy Bioscience Holding Company, Inc. et al, Case No. 18-cv-12416, D. NJ.)

For more of TINA.org’s coverage of Prevagen, click here.

Print Friendly, PDF & Email

Tags: , ,

Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker

  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect TINA.org’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates